Tafasitamab
Monoclonal antibody
Evidence outlook
Approved: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Large B-Cell Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Treatment of relapsed or refractory follicular lymphoma
- Minjuvi (tafasitamab) with lenalidomide, then monotherapy, for relapsed or refractory DLBCL in adults not eligible for ASCT (approved via licensee InnoCare)
- Minjuvi (conditional) with lenalidomide then monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant; holder Incyte Biosciences Distribution B.V.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
InMIND NCT04680052 · Diffuse Large B-Cell Lymphoma The trial was randomized, double-blind and placebo-controlled in 654 patients, with progression-free survival as a hard cancer endpoint. In the follicular lymphoma population (548 patients) the tafasitamab arm had a significantly lower risk of progression or death than the placebo arm. The primary endpoint was clearly met. Registry: NCT04680052 | 3 | FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First (up to approximately 34 months); FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First (up to 2 years) 2024-02-23 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (1)
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, budoprutug, cemacabtagene ansegedleucel, FT819 and 11 more. Compare all 17 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Large B-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tafasitamab: this drug | Approved | Monoclonal antibody | CD19 | Weak signal | NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Golcadomide | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Rondecabtagene Autoleucel | Phase 3 | Cell therapy | CD19 / CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 2(overall) | Monoclonal antibody | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1(overall) | Antibody–drug conjugate | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1(overall) | — | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1(overall) | Cell therapy | CD19 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(30 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tafasitamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
What to watch
2027 (12)
January 2027 (3)
What to watch
What to watch
What to watch
February 2027 (1)
What to watch
April 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (2)
September 2027 (2)
December 2027 (2)
What to watch
What to watch
2028 (6)
May 2028 (1)
What to watch
July 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (6)
April 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (2)
2031 (2)
September 2031 (1)
What to watch
December 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent